[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-tumors":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,37,63,91,114,137,160,181,208,229,248,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100639720","correlation-analysis-of-gene-characteristics-of-malignant-tumors-with-prognosis-100639720",false,"NCT07622667","Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.\n\nExclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.",[23],"Malignant Tumors","RECRUITING","2026-05-28",{"date":27,"type":28},"2026-06-03","ACTUAL",{"date":30,"type":19},"2026-05-29",{"date":32,"type":19},"2027-06-30",{"name":34,"class":35},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100601571","phase-1-a-study-of-lm-350-in-subjects-with-advanced-solid-tumours-100601571","NCT07112222","A Study of LM-350 in Subjects With Advanced Solid Tumours","A Phase I\u002FII, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.\n2. Participant must be ≥18 years or the legal age of consent at the time of signing the ICF.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Life expectancy ≥ 3 months.\n5. Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.\n6. Pre-treatment archived tumour tissue (within 3 years) or on-treatment tumour biopsy could be provided for biomarker analysis.\n7. Must have at least one measurable lesion according to RECIST v1.1.\n8. Adequate organ and bone marrow function as defined by protocol.\n9. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.\n\nExclusion Criteria:\n\n1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.\n2. Subjects who have received treatment with the same targeting.\n3. History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.\n4. Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.\n5. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.\n6. Subjects with uncontrolled tumour-related pain.\n7. Subjects with known central nervous system (CNS) or meningeal metastasis.\n8. Subjects who have clinically uncontrollable third-space fluid accumulation.\n9. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.\n10. Subjects who take systemic corticosteroids (≥ 10 mg\u002Fday of prednisone or equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dose of LM-350.\n11. Has a history of (noninfectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at Screening.\n12. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, and any autoimmune, or prior pneumonectomy.\n13. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-350.\n14. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for \\> 2 weeks prior to the first dose of LM-350.\n15. Subjects with active or a documented history of chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease).\n16. Subjects with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug , orpatients who are currently at the risk of intestinal perforation.\n17. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-350.\n18. Subjects who have severe cardiovascular disease.\n19. Subjects who have uncontrolled or severe illness.\n20. Subjects who have a history of immunodeficiency disease.\n21. HIV infection, active infection including tuberculosis, HBV and HCV infection.\n22. Subjects who have other active malignancies which are likely to require the treatment.\n23. Child-bearing potential female who have positive results in pregnancy test or are lactating.\n24. Subjects who have psychiatric illness or disorders that may preclude study compliance.\n25. Subject who is judged as not eligible to participate in this study by the investigator.",{"count":45,"type":19},80,"INTERVENTIONAL",[48,49],"PHASE1","PHASE2","For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.\n\nFor Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.",[23],"2026-01-22",{"date":54,"type":28},"2026-01-26",{"date":56,"type":28},"2025-08-28",{"date":58,"type":19},"2030-06-30",{"name":60,"class":61},"LaNova Medicines Limited","INDUSTRY",4,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":46,"phases":72,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":36},"100618122","petct-guided-biological-target-volume-delineation-and-dose-optimization-for-radioactive-seed-implantation-therapy-in-malignant-tumors-100618122","NCT07327515","PET\u002FCT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors","A Phase I\u002FII Study of PET\u002FCT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Pathologically or clinically confirmed malignant tumor (solid tumor, lymphoma, or leukemia with a localized lesion suitable for radioactive seed implantation).\n3. Tumor site accessible for image-guided implantation, with a target lesion visible on CT or PET\u002FCT.\n4. Life expectancy of at least 6 months.\n5. Ability to undergo PET\u002FCT imaging (FDG or tumor-specific tracers such as PSMA or FAPI).\n6. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Uncontrolled infection or active systemic inflammatory disease.\n3. Severe cardiopulmonary dysfunction that contraindicates interventional procedures (e.g., heart failure, severe COPD).\n4. Coagulation disorders (INR \\> 1.5 or platelet count \\\u003C 50 × 10⁹\u002FL).\n5. Known allergy or intolerance to radiopharmaceuticals or iodinated contrast media.\n6. Prior radiation therapy overlapping with the planned implantation area.\n7. Participation in another clinical trial within the past 30 days that may interfere with study results.\n8. Any medical or psychosocial condition considered unsuitable for study participation by the investigators (e.g., poor compliance, unstable clinical status).",{"count":71,"type":19},90,[73],"NA","This prospective, open-label Phase I\u002FII trial evaluates a PET\u002FCT-guided planning strategy for radioactive seed implantation therapy in malignant solid tumors. The approach integrates metabolic information from PET\u002FCT into brachytherapy planning to improve the accuracy of biological target volume delineation, enhance dose coverage, and support biologically informed dose delivery. Eligible participants are assigned to one of three arms: conventional CT-guided implantation, PET\u002FCT-guided standard-dose implantation, or PET\u002FCT-guided biologically optimized implantation. All participants undergo image-guided treatment followed by post-implant dosimetric verification and standardized clinical follow-up.\n\nPrimary endpoints include technical success rate, dosimetric superiority, and 6-month local control. Secondary endpoints include dosimetric indices (D90, V100, conformity index, homogeneity index), pain relief, quality of life (EORTC QLQ-C30), treatment-related adverse events (CTCAE v5.0), progression-free survival (PFS), failure-free survival (FFS), and overall survival (OS). Exploratory analyses will evaluate associations between baseline PET metabolic parameters (SUVmax, metabolic tumor volume) and clinical outcomes, assess the feasibility of SUV-guided dose painting, and compare the performance of tumor-specific tracers (such as PSMA and FAPI) with FDG for target delineation and treatment response prediction.\n\nThe central hypothesis is that PET\u002FCT-guided planning-particularly when incorporating biological dose optimization-will achieve superior dosimetric performance and improved local control and survival outcomes compared with conventional CT-guided implantation.",[23],[77,78,79,80],"PET\u002FCT-Guided Brachytherapy","Iodine-125 Seed Implantation","Molecular Imaging-Guided Therapy","Biology-Guided Dose Planning","NOT_YET_RECRUITING","2026-01-02",{"date":84,"type":28},"2026-01-08",{"date":86,"type":19},"2026-01",{"date":88,"type":19},"2028-06-01",{"name":90,"class":35},"Li Min",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":46,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":36},"100614298","phase-2-125i-seed-brachytherapy-combined-with-immunotherapy-for-primary-recurrent-or-metastatic-malignant-tumors-100614298","NCT07277777","125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors","A Prospective, Randomized, Open-Label, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of 125I Seed Interstitial Brachytherapy Combined With Immune Checkpoint Inhibitor Therapy in Patients With Primary, Recurrent, or Metastatic Malignant Tumors Compared With Immune Checkpoint Inhibitor Therapy Alone","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Histologically or clinically confirmed primary, recurrent, or metastatic malignant tumor.\n* At least one measurable lesion according to RECIST 1.1 or iRECIST.\n* Tumor site suitable for 125I seed implantation under CT or PET\u002FCT guidance.\n* Planned to receive or eligible to receive an immune checkpoint inhibitor (ICI).\n* ECOG performance status 0-2.\n* Adequate organ function:\n\nANC ≥ 1.5 × 10⁹\u002FL Platelets ≥ 80 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL AST\u002FALT ≤ 3 × ULN (≤ 5 × ULN for liver metastasis) Creatinine clearance ≥ 50 mL\u002Fmin\n\n* Life expectancy ≥ 3 months.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Prior I-125 seed implantation at the planned treatment site.\n* Active uncontrolled infection or systemic inflammatory disease.\n* Known history of autoimmune disease requiring systemic immunosuppression.\n* Prior treatment with immune checkpoint inhibitors within the last 4 weeks.\n* Uncontrolled coagulopathy or contraindication to interventional seed implantation:\n\nINR \\> 1.5 Platelets \\\u003C 50 × 10⁹\u002FL\n\n* Tumor location that poses unacceptable procedural risk, including inability to obtain a safe puncture path.\n* Severe cardiopulmonary dysfunction (e.g., heart failure, unstable arrhythmia, severe COPD).\n* Pregnancy or breastfeeding.\n* Known allergy or contraindication to radiopharmaceuticals, contrast agents, or anesthesia agents used during implantation.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study (e.g., poor compliance, severe psychiatric disorder).","80 Years",{"count":71,"type":19},[49],"This prospective randomized trial evaluates the efficacy and safety of combining 125I seed interstitial brachytherapy with immune checkpoint inhibitor therapy in patients with primary, recurrent, or metastatic malignant tumors. Immunotherapy has become an important systemic treatment option, yet many patients experience limited benefit due to low tumor immunogenicity, insufficient T-cell infiltration, and an immunosuppressive tumor microenvironment.\n\n125I seed brachytherapy provides continuous low-dose-rate radiation to the tumor, promoting antigen release, enhancing dendritic cell activation, and potentially converting immunologically \"cold\" tumors into more responsive \"hot\" lesions. Integrating localized radiation with systemic immunotherapy may improve tumor response, prolong progression-free survival, and reduce recurrence.\n\nPatients will be randomized 1:1 to receive 125I seed implantation plus immunotherapy or immunotherapy alone. The primary endpoints are objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints include failure-free survival (FFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), local control, recurrence rate, adverse events, and quality of life. Exploratory analyses will assess radiomics features, subgroup responses, and different patterns of recurrence. This study aims to determine whether adding 125I seed brachytherapy enhances the clinical benefits of immunotherapy across diverse malignant tumors.",[23],[104,105,106,107],"lodine-125 Seed Brachytherapy","Immune Checkpoint Inhibitors","Local-Systemic Synergy","Recurrent or Refractory Tumors",{"date":109,"type":28},"2026-01-06",{"date":86,"type":19},{"date":112,"type":19},"2028-01-01",{"name":90,"class":35},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":46,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":36},"100616145","early-phase-1-clinical-application-of-68ga-fl-031-pet-in-the-diagnosis-and-staging-of-malignant-tumors-100616145","NCT07301801","Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors","Inclusion Criteria:\n\n1. The subject or their legal representative is permitted to sign the informed consent form.\n2. The subject has committed themselves to adherence to the prescribed research procedures and to cooperation in the implementation of the entire study process.\n3. Adult patients (aged 18 years or older), irrespective of gender\n4. Patients with a clinical suspicion or confirmed diagnosis of small cell lung cancer, breast cancer, nasopharyngeal carcinoma, and other tumours (for which supporting evidence is provided in the form of serum-related tumour markers, ultrasound, CT, MRI and other image data, and histopathological examination)\n5. The patient is generally in good condition\n6. It is mutually agreed upon by all parties involved that the designated specimen shall be utilised for the purposes of this study.\n\nExclusion Criteria:\n\n1. The patient or his legal representative is unable or unwilling to sign the informed consent\n2. The patient is unable to cooperate with the implementation of the whole process research\n3. The patient has been diagnosed with acute systemic diseases and electrolyte disorders\n4. Pregnant women or lactating women, etc\n5. In the event of other circumstances being deemed by the investigator to be unsuitable for participation in the study, such patients must be excluded on the basis of their known intolerance to SSTR2 targeted substances.",{"count":121,"type":19},10,[123],"EARLY_PHASE1","The project's objective is to recruit patients with clinically confirmed or suspected small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumours for 68Ga-FL-031 PET imaging and 18F-FDG PET imaging. The histopathology of biopsy or surgical specimens was taken as the final diagnostic criteria, and the presence or absence of tumour lesions was confirmed by the aforementioned imaging. The location and nature of the lesion, and the presence or absence of metastasis, were then judged. The objective was to analyse and clarify the diagnostic efficacy of 68Ga-FL-031 PET imaging for the aforementioned malignant tumours. The objective of this study is to analyse the correlation between the 68Ga-FL-031 PET imaging tumour tissue uptake value and the tumour tissue immunohistochemical staining SSTR2 target expression.",[23,126,127],"SSTR2","PET","2025-12-11",{"date":130,"type":28},"2025-12-24",{"date":132,"type":28},"2025-06-12",{"date":134,"type":19},"2026-09-30",{"name":136,"class":35},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":143,"minAge":16,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":36},"100608415","exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy-100608415","NCT07201259","Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\nCollect serum hormone levels post-ICIs treatment to observe the impact of ICIs therapy on female patients.\n\n* Informed consent must be obtained and documented at the research center prior to initiating any trial procedures.\n* Female patients aged 18-38 years.\n* Patients with histologically confirmed solid tumors or soft tissue sarcomas diagnosed via open surgery, laparoscopic surgery, or core needle biopsy.\n* Patients scheduled to receive ICIs therapy or combination therapy including ICIs;\n* Normal ovarian function and fertility prior to treatment, defined as regular menstrual cycles, normal serum FSH, LH, E2, P, and AMH levels, and normal gynecological ultrasound findings;\n* No use of sex hormone medications within 6 months prior to enrollment, including but not limited to estrogens, anti-estrogens hormones, hormonal contraceptives, etc.;\n* No use of antibiotics or probiotics within 3 months prior to enrollment;\n* Availability of blood and stool specimens before and after treatment, with the subject's consent to provide these specimens to the central laboratory for study purposes, including but not limited to: i. Potential gut microbiota-related research. ii. Potential metabolite-related research;\n* Expected survival \\>12 weeks;\n* ECOG performance status 0-2;\n* Adequate organ function, including:\n* Bone marrow function: Neutrophil count ≥1500\u002FµL; Platelet count ≥100,000\u002F µL; Hemoglobin ≥10g\u002FdL\n* Liver function: Total bilirubin ≤1.5 times upper limit of normal (ULN) or direct bilirubin ≤1.0 times ULN; AST and ALT ≤2.5 times ULN, must be ≤5 times ULN if liver metastases present\n* Renal function: Serum creatinine ≤1.5 times ULN, or creatinine clearance\n\n  * 60 mL\u002Fmin (calculated using Cockcroft-Gault formula) ;\n* Understand the trial protocol and have the ability to comply with the trial plan throughout its duration, including cooperating with any required treatments, examinations, tests, follow-ups, and questionnaires;\n* Patient is willing to cooperate with ICIs treatment and subsequent follow-up.\n\nExclusion Criteria:\n\n* Individuals involved in the planning or implementation of the study;\n* Concurrent use of other tumor treatment modalities during the study, including but not limited to: chemotherapy, radiotherapy, immunotherapy, microbial therapy, traditional Chinese medicine, and other investigational therapies;\n* History of bilateral ovarian-related surgery;\n* Patients with prior radiotherapy or chemotherapy causing irreversible damage to ovarian function;\n* Individuals with known allergy to ICIs or their components;\n* Patients with known non-response to immunomodulatory therapy;\n* Patients with unexplained menstrual irregularities or long-term hormone medication use;\n* Patients with chronic gastrointestinal disease or known dysbiosis (e.g., Crohn's disease, ulcerative colitis);\n* Patients who frequently consume fermented foods;\n* Patients who underwent major surgery within 3 weeks prior to study initiation or have not yet recovered from surgery;\n* Subjects with other malignancies within the past 3 years;\n* Patients with severe, uncontrolled medical conditions or those deemed by the investigator to be generally unsuitable for study participation, including but not limited to: active viral infections such as HIV, hepatitis B, hepatitis C; severe cardiovascular disease, uncontrolled ventricular arrhythmias, myocardial infarction within the past 3 months; uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other psychiatric conditions affecting informed consent; uncontrolled hypertension despite medication; immunodeficiency (excluding splenectomy) or other conditions the investigator deems likely to expose the subject to high toxicity risk;\n* Any history or current clinical evidence suggesting potential for confounding study results, compromising patient compliance throughout the study, or acting against the patient's best interests;\n* Receipt of platelet or red blood cell transfusion within 3 days prior to initiation of study drug treatment;\n* Pregnant or lactating patients, or patients planning pregnancy during the study period.\n* Clinically unresolved prior treatment toxicity (≥ Grade 2, excluding alopecia, neuropathy, lymphopenia, or skin hypopigmentation);","FEMALE","38 Years",{"count":146,"type":19},40,"The goal of this observational study is to evaluate the impact of Immune Checkpoint Inhibitor (ICI) treatment on ovarian function and fertility, and to explore the role of gut microbiota in female cancer patients of reproductive age (18-38 years) receiving ICI therapy. The main questions it aims to answer are:\n\nDoes ICI treatment alter serum hormone levels (FSH, LH, E2, P, AMH) associated with ovarian function and fertility?\n\nAre there differences in gut microbiota composition and metabolites between patients with different ovarian function and fertility outcomes after ICI treatment?\n\nWhat are the potential mechanisms by which gut microbiota influences ovarian function and fertility in patients receiving ICIs?\n\nResearchers will compare patients with preserved ovarian function versus those with impaired ovarian function after ICI treatment to identify differences in gut microbiota and metabolic profiles.\n\nParticipants will:\n\nProvide blood samples (10 ml per collection) at enrollment and after each of the 6 treatment cycles for hormone level testing and potential future analyses.\n\nProvide stool samples at the same time points for gut microbiota metagenomic sequencing and metabolite analysis.\n\nUndergo regular clinical assessments and follow-ups as part of their standard ICI treatment.",[23],[150],"immune checkpoint inhibitors, female, ovarian function, fertility","2025-09-23",{"date":153,"type":28},"2025-10-01",{"date":155,"type":19},"2025-10-10",{"date":157,"type":19},"2026-10-10",{"name":159,"class":35},"West China Second University Hospital",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":20,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100603137","the-predictive-value-of-serum-histone-succinylation-in-malignant-solid-tumors-100603137","NCT07132606","The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors","Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors","Inclusion Criteria:\n\nCase Group:\n\n* Aged ≥18 years, regardless of sex；\n* Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；\n\nControl Group:\n\n* Aged ≥18 years, regardless of sex；\n* Non-cancer participants enrolled through health screenings；\n\nExclusion Criteria:\n\n* Pregnant individuals；\n* Individuals with serious mental disorders or communication barriers；\n* Other conditions deemed by investigators to contraindicate study participation；",true,{"count":169,"type":19},1000,"6 Months","In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.\n\nThis project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from \"gene-driven\" to \"epigenetic-metabolic-driven\" early detection.",[23],"2025-08-17",{"date":175,"type":28},"2025-08-20",{"date":175,"type":19},{"date":178,"type":19},"2026-08-01",{"name":180,"class":35},"Yinghua Ji",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":46,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":36},"100593269","phase-1-application-of-kras-vaccine-in-the-treatment-of-kras-mutated-malignancies-100593269","NCT07004244","Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies","Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies","Key Inclusion Criteria:\n\n* Male or female participants ≥18 years of age.\n* Participants with solid tumors confirmed to carry KRAS mutations.\n* At least one measurable lesion according to RECIST 1.1 criteria.\n* ECOG physical condition score: 0-1 point.\n* Adequate organ and bone marrow function.\n* Ability to understand and voluntarily provide written informed consent before trial participation.\n\nCohort-specific Inclusion Criteria:\n\nCohort 1:\n\n* Failure of prior standard therapy, intolerance to standard therapy, ineligibility for standard therapy, or absence of a standard treatment regimen.\n* Life expectancy ≥3 months.\n\nCohort 2:\n\n* Newly diagnosed, treatment-naïve lung adenocarcinoma confirmed by pathology (histology\u002Fcytology).\n* Resectable disease classified as stage IB-IIIA per AJCC 9th edition criteria.\n* KRAS G12C\u002FG12D\u002FG12V\u002FG13D mutation-positive by genomic testing.\n\nExclusion Criteria:\n\n* Patients with a history of other malignancies.\n* Presence of primary central nervous system (CNS) tumors, active CNS metastatic tumors, or carcinomatous meningitis, either historically or identified during screening.\n* Uncontrolled moderate to massive serous cavity effusion.\n* Confirmed presence of other classic gene variants.\n* Known cardiac clinical symptoms or diseases that are poorly controlled.\n* Unstable thrombotic events (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 6 months prior to screening.\n* Any active autoimmune disease or a history of autoimmune disease.\n* Uncontrolled clinical disorders, psychiatric illnesses, or other significant diseases as assessed by the investigator that may interfere with informed consent, compromise interpretation of trial results, pose risks to participants, or otherwise hinder the achievement of trial objectives.\n* History of interstitial pneumonia or suspected interstitial pneumonia; or pulmonary abnormalities that may interfere with the detection or management of suspected drug-related pulmonary toxicity during the trial.\n* Hypersensitivity to the investigational drug (including any excipients).\n* Patients who received anti-tumor therapy within 4 weeks prior to the first dose, or those with unresolved adverse reactions (except alopecia) from prior anti-tumor therapy (NCI CTCAE \\> grade 1).\n* Systemic use of corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose.\n* Participants who received drugs of the same class within 6 months prior to the first dose.\n* Prior organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection.\n* Active tuberculosis (TB) or a history of active TB; or severe acute\u002Fchronic infections requiring systemic treatment.\n* Pregnant or lactating women.\n* Any other factors deemed by the investigator to render the participant unsuitable for trial participation.",{"count":189,"type":19},20,[48],"The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.",[23],[194,195,196,197,198],"KRAS-mutated malignancies","mRNA vaccines","treatment","safety","efficacy","2025-06-17",{"date":201,"type":28},"2025-06-24",{"date":203,"type":28},"2025-06-05",{"date":205,"type":19},"2027-12-31",{"name":207,"class":35},"Sichuan University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":215,"targetDuration":4,"studyType":46,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},"100566083","phase-1-study-of-lm-299-in-subjects-advanced-malignant-tumors-100566083","NCT06650566","Study of LM-299 in Subjects Advanced Malignant Tumors","A Phase I\u002FII, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.\n2. Participant must be 18- 18 years or the legal age of consent at the time of signing the ICF.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Life expectancy ≥ 3 months.\n5. Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.\n6. Pre-treatment archived tumour tissue (within 5 years) or fresh samples could be provided for biomarker analysis.\n7. Must have at least one measurable lesion according to RECIST v1.1.\n8. Adequate organ and bone marrow function as defined by protocol.\n9. Female subjects of childbearing potential or male subjects with partners of childbearing potential agree to use highly effective contraception.\n10. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.\n\nExclusion Criteria:\n\n1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-299.\n2. Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-299.\n3. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.\n4. Subjects with uncontrolled tumour-related pain.\n5. Subjects with known central nervous system (CNS) or meningeal metastasis.\n6. Qualitative urine protein results ≥ 3+.\n7. Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to 1st dosing of LM-299.\n8. Any life-threatening bleeding event that occurred within 3 months prior to 1st dosing of LM-299.\n9. Subjects with esophageal or gastric varices requiring immediate intervention or a history of variceal bleeding .\n10. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis.\n11. Subjects who have clinically uncontrollable third-space fluid accumulatio.\n12. Radiographic evidence of tumor invading surrounding vital organs or the risk of esophagotracheal fistula or esophagopleural fistula, tumor surrounding or invading the major blood vessels, or presence of intratumoral cavity formation.\n13. History of gastrointestinal perforation and\u002For fistula within 6 months prior to the first dose of the study drug.\n14. Patients with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug or patientswho are currently at the risk of intestinal perforation.\n15. Subjects who are known to be allergic to antibody treatment.\n16. Subjects who take systemic corticosteroids (≥ 10 mg\u002Fday of prednisone or equivalent) for more than 7 days within 2 weeks prior to the first dose of LM-299.\n17. Subjects with the known history of autoimmune disease.\n18. Patients with a history of active or previously confirmed inflammatory bowel disease.\n19. Patients with a history of or currently having interstitial pneumonia requiring systemic corticosteroid treatment.\n20. Received live vaccines or attenuated live vaccines within 28 days prior to the first dose of the study drug.\n21. Currently using anticoagulants such as therapeutic doses of heparin or vitamin K antagonists.\n22. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-299 (excluding tumour biopsy, puncture, etc.).\n23. Subjects who have severe cardiovascular and and cerebrovascular diseases.\n24. Patients with severe infections within 4 weeks prior to the first dose.\n25. Patients with a history of immunodeficiency.\n26. Individuals with HIV infection, active HBV or HCV infection .\n27. Patients with known active tuberculosis (TB). Suspected active TB should be ruled out through clinical examination.\n28. Patients who have had other malignancies within 5 years prior to the first dose of the study drug.\n29. Women of childbearing age who test positive for pregnancy within 7 days prior to the first dose of the study drug or are breastfeeding.\n30. Individuals with known psychiatric disorders or illnesses that may affect adherence to the trial.\n31. Patients with local or systemic diseases caused by non-malignant tumors.\n32. Subject who is judged as not eligible to participate in this study by the investigator.",{"count":216,"type":19},108,[48,49],"For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours..\n\nFor Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.",[23],"2025-04-29",{"date":222,"type":28},"2025-05-02",{"date":224,"type":28},"2024-10-09",{"date":226,"type":19},"2027-07",{"name":60,"class":61},6,{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":46,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":246,"locationsCount":36},"100588672","phase-1-a-phase-i-clinical-study-of-sss59-monotherapy-in-patients-with-advanced-malignant-tumors-100588672","NCT06944444","A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Histologically and\u002For cytologically documented local advanced or recurrent or metastatic malignancies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Any remaining AEs \\> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Underwent major surgery within 4 weeks prior to first dosing.\n* The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","75 Years",{"count":238,"type":19},154,[48],"This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.",[23],"2025-04-27",{"date":220,"type":28},{"date":242,"type":28},{"date":205,"type":19},{"name":247,"class":61},"Shenyang Sunshine Pharmaceutical Co., LTD.",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":255,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":36},"100573994","clinical-application-of-99mtc-fdph46-spectct-imaging-in-malignant-solid-tumor-a-prospective-exploratory-study-100573994","NCT06753513","Clinical Application of 99mTc-FDPH46 SPECT\u002FCT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study","99mTc；FAPI；mCi","Inclusion Criteria:\n\n1. Patients who are clinically suspected or diagnosed with malignant solid tumors.\n2. Ages between 18 to 80 years old.\n3. Stable vital signs, ECOG score of 0-2, capable of tolerating and cooperating with the 99mTc-FDPH46 SPECT\u002FCT examination.\n4. Subjects who are willing to undergo the 99mTc-FDPH46 SPECT\u002FCT examination and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Those who can not understand, comply with the research protocol or are unable to sign the informed consent form.\n2. Contraindications for SPECT imaging (including pregnant women, nursing women, women of childbearing age with recent plans to conceive, etc.).\n3. Unstable vital signs, ECOG score \\>2, unable to tolerate or cooperate with the 99mTc-FDPH46 SPECT\u002FCT examination process.",{"count":189,"type":19},"The goal of this observational study aims to preliminarily evaluate the diagnostic efficacy of 99mTc-FDPH46 SPECT\u002FCT in malignant solid tumors (compared to the pathological gold standard). The main questions it aims to answer are:\n\n* What is the diagnostic efficacy of 99mTc-FDPH46 in malignant solid tumors, compared to the pathological gold standard?\n* What is the biodistribution, tumor uptake and safety of 99mTc-FDPH46 SPECT\u002FCT in patients with malignant solid tumors?\n\nParticipant Will:\n\n• Patients with clinically suspected or diagnosed malignant solid tumors who are willing to undergo 99mTc-FDPH46 SPECT\u002FCT examination and sign an informed consent form.",[23,258],"Solid Tumor Malignancy",[260,261,262,263],"99mTc","FDPH46","SPECT","Malignant Solid Tumor","2024-12-22",{"date":266,"type":28},"2024-12-31",{"date":268,"type":19},"2024-12-28",{"date":270,"type":19},"2026-12-31",{"name":272,"class":35},"Zhejiang University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":46,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":293},"100486584","phase-1-a-phase-iii-study-of-lm-101-injection-in-patients-with-advanced-malignant-tumors-100486584","NCT05615974","A Phase I\u002FII Study of LM-101 Injection in Patients With Advanced Malignant Tumors","A Phase I\u002FII, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.\n2. Aged ≥18 years old, male or female.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Life expectancy ≥ 3 months.\n5. Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy.\n6. At least one evaluable lesion.\n7. Subjects in the combination therapy group must have Archived Samples or fresh tumor tissue specimens are required for testing.\n8. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose:\n9. Women of childbearing potential (WOCBP) must agree to use highly effective methods of contraception prior to study entry, during the study and for 6 months after the last dose of study drug.\n10. Subjects who can communicate well with investigators and understand and adhere to the requirements of this study.\n\nExclusion Criteria:\n\n1. Subject has received prior investigational therapy directed at the same target therapy.\n2. Subjects has participated in any other interventional clinical trial within 21 days prior to the first dosing of LM-101.\n3. Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.\n4. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.\n5. Poorly controlled tumor-related pain.\n6. Subjects with symptomatic\u002Factive central nervous system (CNS) metastases.\n7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n8. Subjects with known hypersensitivity to antibody therapy.\n9. Subjects who take systemic corticosteroids (\\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medicationswithin 2 weeks prior to the first dosing of LM-101.\n10. Subjects with the known history of autoimmune disease with the exception of subjects with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone.\n11. Subject who has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.\n12. Use of any live attenuated vaccines within 28 days prior to the first dosing of LM-101.\n13. Subjects who are using therapeutic doses of anticoagulants such as heparin or vitamin K antagonists.\n14. Subjects who received major surgery or interventional treatment within 28 days prior to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.).\n15. Subjects who have history of severe cardiovascular disease.\n16. Subjects who have uncontrolled or severe illness.\n17. Subjects who have a history of immunodeficiency disease.\n18. HIV infection, active tuberculosis or active HBV and HCV infection.\n19. Subjects who have Known history of active tuberculosis.\n20. Subjects who have other active invasive cancers, other than the one treated in this trial, within 5 years prior to screening.\n21. Child-bearing potential female who have positive results in pregnancy test or are lactating.\n22. Subject who have a known psychiatric diseases or disorders that may affect compliance with the trial.\n23. Subject who is judged as not eligible to participate in this study by the investigator.",{"count":281,"type":19},139,[48,49],"This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and\u002For the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors",[23],"2024-12-16",{"date":287,"type":28},"2024-12-19",{"date":289,"type":28},"2023-01-11",{"date":291,"type":19},"2028-01-11",{"name":60,"class":61},5]